What were the key takeaways from Alignment Healthcare's earnings call?

What guidance did Alignment Healthcare's management provide for the next earnings period?

What is the market's earnings forecast for Alignment Healthcare next quarter?

What is Alignment Healthcare's gross profit margin?

What is Alignment Healthcare's latest dividend and current dividend yield?

What factors drove the changes in Alignment Healthcare's revenue and profit?

What were the key takeaways from Alignment Healthcare’s earnings call?

Did Alignment Healthcare beat or miss consensus estimates last quarter?

- **Revenue Growth**: 46% YoY to $3.9B, driven by 25% membership expansion. 
- **Profitability**: Adjusted EBITDA margin improved 270bps to 2.8%, with 2026 guidance of $133-163M. 
- **Ex-California Expansion**: 80%+ growth in non-CA markets, targeting 1M+ members. 
- **AI Transformation**: 30+ AI use cases in pipeline, prioritizing administrative efficiency. 
- **Rate Resilience**: Clinically-led model positions to outperform in flat rate environment. 
- **Financial Strength**: $604M cash, no near-term credit facility draw needed.

**【CEO Summary Section】**
- **Revenue and Membership Growth**: Q4 2025 revenue reached $1 billion (44% YoY growth), with total annual revenue of $3.9 billion (46% YoY). Health plan membership grew 25% YoY to 236,300, with 80%+ growth in ex-California markets. 
- **Operational Efficiency**: Achieved adjusted EBITDA of $110 million (2.8% margin), up 270 basis points YoY. Ex-California membership reached 38,000 (16% of total), with 5-star ratings in key markets.
- **2026 Outlook**: Guidance for 2026 EBITDA of $133-163 million reflects disciplined growth, balancing membership expansion with margin management. 
- **Strategic Focus**: Investing in AI workflows, clinical model scalability, and new market entry. 2026 AEP resulted in 275,300 members (31% YoY growth), with 80% of gross sales from planned switchers.

**【CFO Financial Commentary】**
- **2025 Financials**: GAAP revenue $3.9B, adjusted gross profit $495M (87.5% MBR). Adjusted EBITDA $110M (2.8% margin). 
- **2026 Guidance**: 
  - Membership: 292,000-298,000 (31% YoY growth)
  - Revenue: $5.14-5.19B (31% YoY)
  - Adjusted EBITDA: $133-163M
- **Key Drivers**: V28 risk model phase-in, dual-eligible member mix (higher initial MBR), and Part D profitability. 
- **Liquidity**: $604M cash, $200M credit facility. 

**【Q&A Highlights】**
- **Rate Environment**: CMS 2027 rate notice flat at 0.9%, but company expects to outperform through clinical model. 
- **AI Investment**: 30+ AI use cases in development, focusing on administrative efficiency (e.g., member services, financial reporting). 
- **Market Expansion**: Targeting new states with strong provider relationships, aiming for <4% market share in ex-California counties. 
- **MLR Seasonality**: 2026 MBR expected to be flat Q1-Q2, rising in Q3-Q4 due to Part D seasonality. 
- **Risk Adjustment**: <1% exposure to unlinked chart reviews, compliant with CMS documentation standards.

Alignment Healthcare, Inc.(ALHC)-20260227-2025 Q4 Earnings call transcript

- **Revenue Growth**: 44% YoY to $994M, with 26% membership expansion to 229,600. Full-year EBITDA raised to $94M.
- **Star Excellence**: 100% of members in 4+ star plans; California HMO at 4 stars for 9th year, North Carolina/Nevada at 5 stars.
- **2026 Outlook**: AEP growth target of 20%+ supported by early strong retention and gross adds. Star rating improvements and CMS Equity Index changes provide margin upside.
- **Operational Strength**: MBR 87.2% (120bps YoY), SG&A 9.6% (120bps YoY decline). Part D stability despite IRA changes.
- **Investment Focus**: AI/automation, Stars durability, and direct provider engagement driving replicable success in new markets.
- **Risk Management**: RADV compliance strong; no material risk from CMS reviews. Part D margin assumptions cautious but stable.


**【CEO Summary Section】**
- Health plan membership reached 229,600, up 26% year-over-year, driving total revenue of $994 million (44% YoY growth). Adjusted EBITDA of $32 million exceeded high-end guidance, with full-year outlook raised to $94 million.
- Star ratings improved, with 100% of members in 4+ star plans for 2027. California HMO earned 4 stars for the 9th consecutive year, while North Carolina and Nevada contracts achieved 5 stars.
- 2026 AEP growth target of at least 20% is supported by disciplined member acquisition and high-touch care delivery. Early AEP results show strong retention and gross adds.
- Investments in AI (AVA clinical stratification), back-office automation, and Stars durability are key to replicating success in new markets.

**【CFO Financial Commentary】**
- Q3 2025: Adjusted gross profit $127 million (58% YoY), MBR 87.2% (120bps YoY improvement). Adjusted SG&A ratio 9.6% (120bps YoY decline). Full-year 2025 guidance raised to $3.93B-$3.95B revenue, $474M-$483M adjusted gross profit.
- Part D performance stable despite IRA changes; Q3 utilization trends moderate. Q4 2025 guidance: revenue $995M-$1.01B, adjusted EBITDA -$9M to -$1M.
- Cash position $644M, supported by medical expense timing benefits. Full-year 2025 cash flow expected to remain strong despite seasonal Q4 utilization.

**【Q&A Key Highlights】**
- **Growth Strategy**: 80-85% of new members are switches, with no material risk from aggressive growth. 2026 AEP early results show strong retention and gross adds, with 2 weeks of activity already encouraging.
- **Star Ratings**: Raw score improvement in California HMO to 4.05/5.0, driven by AVA's data integration. CMS Health Equity Index changes may provide 0.25-star cushion in 2028.
- **Part D Management**: 2025 execution stable despite IRA changes; 2026 bids prudent but cautious. Part D margin assumptions remain conservative.
- **Market Expansion**: Replicating California model in North Carolina/Nevada with 5-star contracts. New market entries for 2027 will focus on high-provider alignment geographies.
- **Cost Control**: SG&A timing benefits in Q3 ($3M) expected to reverse in Q4, leaving full-year SG&A unchanged. AI/automation investments to drive long-term efficiency.
- **RADV Preparedness**: Documentation processes robust; no material risk from CMS compliance reviews.
- **MLR Performance**: New market MLRs consistent with California model, supported by shared-risk IPA arrangements.
- **Brand Investment**: Initial marketing efforts (e.g., LinkedIn ads) to enhance member acquisition channels, reducing reliance on broker commissions.


Alignment Healthcare, Inc. (ALHC) Q3 2025 Earnings Call Transcript

- **Revenue & Profit Growth**: $1B revenue (+49% YoY), $46M EBITDA (4.5% margin) vs. $10M-$18M guidance. Full-year EBITDA raised to $69M-$83M. 
- **Efficiency Metrics**: 86.7% MBR (200bps YoY), 8.8% SG&A ratio (160bps YoY). 
- **Strategic Momentum**: 2026 membership guidance +20%, 100% members in 4+ star plans. Free cash flow positive in 2025. 
- **Operational Strength**: Inpatient admissions 140s vs. 150-160 historical, Part D MBR stable. 
- **Competitive Edge**: 7x industry growth rate, lowest SG&A ratio in MA, AI-driven care navigation. 


**【CEO Summary Section】**
- Health plan membership reached 223,700 (28% YoY growth), driving $1 billion in revenue (+49% YoY). Adjusted EBITDA of $46 million (4.5% margin) exceeded guidance, with a 360bps margin expansion. 
- MBR improved to 86.7% (200bps YoY), SG&A ratio dropped to 8.8% (160bps YoY). First-half adjusted EBITDA of $66 million exceeded full-year initial guidance. 
- 2026 guidance raised for membership (229,000-234,000), revenue ($3.885B-$3.910B), and EBITDA ($69M-$83M). 
- Strategic focus on AI-driven care navigation, provider partnerships, and V28 risk model navigation. 100% of 2026 members in 4+ star plans. 

**【CFO Financial Commentary】**
- Q2 gross profit $135M (+76% YoY), MBR 86.7% (200bps YoY). Final 2024 sweep added $14M, but core metrics still beat guidance. 
- SG&A of $89M (8.8% of rev) included $6M timing benefit, reversing in H2. Full-year SG&A ratio expected at 9.9% (130bps YoY). 
- 2025 full-year guidance: revenue $3.885B-$3.910B, EBITDA $69M-$83M. 
- Part D MBR stable, but Q4 may see IRA-driven seasonality. Free cash flow positive for 2025. 

**【Q&A Highlights】**
- **SG&A Efficiency**: 8.8% ratio vs. peers; 2025 full-year target 9.9%. AI investments to further automate workflows. 
- **Provider Alignment**: IPA partnerships reduce inpatient admissions (low-140s vs. 150-160 historical). Shared savings model drives provider loyalty. 
- **Utilization Trends**: Stable medical trend, Part D higher due to drug cost escalation. 
- **2026 Bids**: V28 phase-in supports margin expansion; 20%+ growth target maintained. 
- **Competitive Position**: 7x industry membership growth rate, 100% 2026 members in 4+ star plans. 
- **Cash Flow**: $504M in Q2, free cash flow positive for 2025. 


Alignment Healthcare, Inc. (ALHC) Q2 2025 Earnings Call Transcript

- **Q1 2025 Standout Performance**: 32% membership growth, 47% revenue surge, and 87% gross profit expansion highlight execution excellence.
- **Operational Superiority**: 250bps MBR improvement and sub-150 inpatient admissions per 1,000 demonstrate clinical model scalability.
- **2026 Growth Catalysts**: 8% rate increase, 100% 4+ stars in California, and B28 risk model advantage set up for margin expansion.
- **Leadership Transition**: Smooth CFO handover positions for long-term strategic execution.


**【CEO Summary Section】**
- **Strong Q1 2025 Results**: Health plan membership grew 32% YoY to 217,500, driving $927M revenue (+47% YoY). Adjusted gross profit of $107M (+87% YoY) and EBITDA of $20M (+410bps margin expansion) exceeded guidance.
- **Operational Excellence**: MBR improved 250bps to 88.4%, with inpatient admissions per 1,000 at 153 (California) and 145 (ex-California), both below expectations. Stars rating advantage widens in 2026, with 100% California members in 4+ stars vs. 59% peers.
- **Future Growth Strategy**: Raise 2025 guidance midpoints across metrics. Invest in back office, member engagement, and provider partnerships. Target 2026 new market launches with $3.8B+ revenue outlook.
- **Leadership Transition**: CFO Thomas Freeman transitions to Strategic Advisor; Jim Head joins as CFO with 30+ years healthcare experience.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: $927M includes 32% YoY membership growth and higher Part D PMPM from Inflation Reduction Act. Adjusted SG&A of $87M (9.4% of revenue) reflects 160bps YoY margin improvement.
- **Profitability Drivers**: Favorable inpatient utilization, Part D MBR outperformance, and prior period IV&R reserve releases. Full-year 2025 EBITDA guidance raised to $49M midpoint.
- **2026 Outlook**: 8% weighted average rate increase vs. 5% in 2025. B28 risk model phase-in benefits and CMS rate notice adjustments position for margin expansion.

**【Q&A Key Themes】**
- **MLR Performance**: Q1 outperformance driven by stable inpatient utilization and Part D MBR favorability, expected to reverse in H2. 2025 Part D MVR outlook unchanged.
- **Market Competition**: 2026 stars and B28 advantages vs. peers. Global cap IPA alignment on risk-sharing; focus on at-risk member growth.
- **AVA Technology**: Continuous improvement in care management modules; targeting 20% high-risk population with proactive support.
- **Rate Environment**: Thrive in both rate compression and expansion; 2026 rate increase supports margin and growth objectives.


Alignment Healthcare (ALHC)-1 May 25-2025 Q1 Earnings call transcript

- **Breakout Membership Growth**: 59% YoY to 189,100 members, with ex-California markets growing over 100% YoY.
- **Profitability Milestone**: First year of adjusted EBITDA profitability ($1 million) and 200 bps margin expansion.
- **Star Rating Dominance**: 98% of members in 4+ star plans vs. 64% industry average, enabling 2025 membership growth of 20%+.
- **2025 Outlook**: $3.72-3.78 billion revenue (+40% YoY), $35-60 million EBITDA, and $600 million embedded gross profit from maturing cohorts.
- **Financial Strength**: $471 million cash post-Q4 debt refinancing, reducing interest costs by $10 million annually.


**【CEO Summary Section】**
- **Membership Growth**: Ended Q4 2024 with 189,100 members, up 59% YoY, exceeding the high end of initial guidance by 25,000 members. Ex-California markets grew over 100% YoY, with Nevada surpassing 10,000 members.
- **Revenue Performance**: Q4 revenue of $701 million (+51% YoY, +61% excluding ACO REACH), full-year revenue of $2.7 billion (+48% YoY). Adjusted EBITDA turned positive at $1 million for the year, marking first profitability as a public company.
- **Gross Margin Expansion**: Consolidated MBR improved 200 bps YoY to 87.5%, driven by clinical resource utilization (400+ clinical staff, 4% of expenses per at-risk member). Adjusted gross profit of $88 million in Q4, $303 million annually.
- **Star Ratings & Market Position**: 95% of California members in 4+ star plans vs. 68% for competitors. 98% of total members in 4+ star plans, 34% better than industry average. 2026 payment year will see 100% California members in 4+ star plans.
- **2025 Outlook**: Membership guidance of 227,000-233,000 (+35% YoY), revenue of $3.72-3.78 billion (+40% YoY). Embedded gross profit opportunity of $600 million from maturing cohorts (50% of members in year 1/2).

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net income $420 million, Non-GAAP EPS $1.08 (exceeds expectations). Adjusted EBITDA $1 million (vs. -$11 million in 2023). Operating expenses declined 5% YoY due to cost control and scale benefits.
- **2025 Guidance**: Adjusted EBITDA of $35-60 million (+130 bps margin expansion). Revenue growth driven by Part D changes (Inflation Reduction Act) and V28 risk model phase-in. CAPEX of $30-35 million for 2025.
- **Balance Sheet**: $471 million in cash post-Q4 convertible note issuance, reducing annual interest expense by $10 million.

**【Q&A Highlights】**
- **Part D Impact**: 2025 MBR seasonality flattens due to IRA changes, with Q1 MBR lower than prior years. Full-year MBR expected to improve sequentially but at a slower rate.
- **Ex-California Growth**: 28% growth in California, 100%+ in ex-California. Nevada 5-star contract and strong medical management (144 admissions/1,000) drive reimbursement and cost control.
- **MLR vs. Peers**: 2024 MBR up 130 bps YoY vs. industry peers up 500-600 bps. 2025 guidance embeds 42% gross profit growth, driven by cohort maturation and benefit design changes.
- **Cash Flow & Capital Allocation**: 2025 free cash flow expected to support organic growth without external financing. CapEx focused on care delivery infrastructure and automation.


Actual	-0.3063	-0.25	-0.26	-0.27	-0.23	-0.06	-0.22	-0.31	-0.2	-0.15	-0.19	-0.25	-0.25	-0.13	-0.14	-0.16	-0.05	0.07	0.02	-0.05
Forecast	-0.1883	-0.1052	-0.1637	-0.2768	-0.2304	-0.2248	-0.2277	-0.2763	-0.2286	-0.183	-0.1668	-0.1984	-0.2073	-0.1183	-0.1101	-0.1857	-0.1267	-0.0717	-0.0814	-0.1537
Surprise	-62.67%	-137.64%	-58.83%	+2.46%	+0.17%	+73.31%	+3.38%	-12.20%	+12.51%	+18.03%	-13.91%	-26.01%	-20.60%	-9.89%	-27.16%	+13.84%	+60.54%	+197.63%	+124.57%	+67.47%

ALHC

ALHC fundamentals

ALHC Q4 2025 Earnings

Earnings Call

You can ask Aime

ALHC

ALHC fundamentals

ALHC Q4 2025 Earnings

Earnings Call

ALHC Earnings Call Summary for Q4/20255:00 PM on Feb 26, 2026

ALHC Earnings Call Summary for Q3/20255:00 PM on Oct 30, 2025

ALHC Earnings Call Summary for Q2/20255:00 PM on Jul 30, 2025

ALHC Earnings Call Summary for Q1/20255:00 PM on May 1, 2025

ALHC Earnings Call Summary for Q4/20245:00 PM on Feb 27, 2025

You can ask Aime